Evan B Shereck1, Erin Cooney, Carmella van de Ven, Phyllis Della-Lotta, Mitchell S Cairo. 1. Department of Pediatrics, Columbia University, and Division of Pediatric Hematology and Blood and Marrow Transplantation, Morgan Stanley Children's Hospital of New York-Presbyterian, Herbert Irving Comprehensive Cancer Center, New York, NY 10032, USA.
Abstract
BACKGROUND: Prophylaxis with ganciclovir or foscarnet post allogeneic stem cell transplant (AlloSCT) reduces cytomegalovirus (CMV) disease. Combination ganciclovir/foscarnet is more effective than monotherapy in HIV patients with CMV retinitis. We hypothesized that alternate day ganciclovir and foscarnet for the prevention of CMV during the first 100 days after AlloSCT would be safe and effective. PROCEDURE: Fifty-three pediatric and adolescent AlloSCT recipients receiving 57 AlloSCTs where donors and/or recipients were CMV seropositive received ganciclovir (5 mg/kg/48 hr) alternating with foscarnet (90 mg/kg/48 hr) from myeloid recovery (>or=ANC 750/mm3) until Day +100. RESULTS: Patients were: M:F 31:22; age 6 years (0.8-18 years); donor sources: 25 related peripheral blood/bone marrow, 3 unrelated adult peripheral blood, 26 unrelated cord blood, and 3 related cord blood. GVHD prophylaxis included tacrolimus/mycophenolate mofetil (MMF). Median-nucleated and CD34 cell counts were 7.3x10(8)/kg and 5.07x10(6)/kg, respectively, for BM/PBSC; 4.07x10(7)/kg and 1.69x10(5)/kg, respectively, for CB. Despite a 36.5% probability of Grades II-IV acute GVHD, no patient developed systemic CMV disease. Five percent had Grade IV hematological toxicity that required discontinuation of ganciclovir. Twenty-five percent required discontinuation of foscarnet secondary to electrolyte abnormalities and/or renal dysfunction that were presumed to be multifactorial in origin. Probability of 1-year overall survival was 58.8%. CONCLUSIONS: Alternate day ganciclovir/foscarnet in AlloSCT recipients where recipient and/or donor is seropositive appears to be tolerable and 100% effective in preventing CMV systemic disease. A randomized study will be required to determine if this approach is superior to other CMV prophylactic designs. Copyright (c) 2006 Wiley-Liss, Inc.
BACKGROUND: Prophylaxis with ganciclovir or foscarnet post allogeneic stem cell transplant (AlloSCT) reduces cytomegalovirus (CMV) disease. Combination ganciclovir/foscarnet is more effective than monotherapy in HIVpatients with CMV retinitis. We hypothesized that alternate day ganciclovir and foscarnet for the prevention of CMV during the first 100 days after AlloSCT would be safe and effective. PROCEDURE: Fifty-three pediatric and adolescent AlloSCT recipients receiving 57 AlloSCTs where donors and/or recipients were CMV seropositive received ganciclovir (5 mg/kg/48 hr) alternating with foscarnet (90 mg/kg/48 hr) from myeloid recovery (>or=ANC 750/mm3) until Day +100. RESULTS:Patients were: M:F 31:22; age 6 years (0.8-18 years); donor sources: 25 related peripheral blood/bone marrow, 3 unrelated adult peripheral blood, 26 unrelated cord blood, and 3 related cord blood. GVHD prophylaxis included tacrolimus/mycophenolate mofetil (MMF). Median-nucleated and CD34 cell counts were 7.3x10(8)/kg and 5.07x10(6)/kg, respectively, for BM/PBSC; 4.07x10(7)/kg and 1.69x10(5)/kg, respectively, for CB. Despite a 36.5% probability of Grades II-IV acute GVHD, no patient developed systemic CMV disease. Five percent had Grade IV hematological toxicity that required discontinuation of ganciclovir. Twenty-five percent required discontinuation of foscarnet secondary to electrolyte abnormalities and/or renal dysfunction that were presumed to be multifactorial in origin. Probability of 1-year overall survival was 58.8%. CONCLUSIONS: Alternate day ganciclovir/foscarnet in AlloSCT recipients where recipient and/or donor is seropositive appears to be tolerable and 100% effective in preventing CMV systemic disease. A randomized study will be required to determine if this approach is superior to other CMV prophylactic designs. Copyright (c) 2006 Wiley-Liss, Inc.
Authors: J Hochberg; L Harrison; E Morris; O Militano; P Brand; S Fabricatore; K Wolownik; M S Cairo Journal: Bone Marrow Transplant Date: 2016-04-18 Impact factor: 5.483
Authors: M Bhatia; Z Jin; C Baker; M B Geyer; K Radhakrishnan; E Morris; P Satwani; D George; J Garvin; G Del Toro; W Zuckerman; M T Lee; M Licursi; R Hawks; E Smilow; L A Baxter-Lowe; J Schwartz; M S Cairo Journal: Bone Marrow Transplant Date: 2014-05-05 Impact factor: 5.483
Authors: Mark B Geyer; Judith S Jacobson; Jason Freedman; Diane George; Virginia Moore; Carmella van de Ven; Prakash Satwani; Monica Bhatia; James H Garvin; Mary Brigid Bradley; Lauren Harrison; Erin Morris; Phyllis Della-Latta; Joseph Schwartz; Lee A Baxter-Lowe; Mitchell S Cairo Journal: Br J Haematol Date: 2011-08-16 Impact factor: 6.998
Authors: P Satwani; Z Jin; P L Martin; M Bhatia; J H Garvin; D George; S Chaudhury; J Talano; E Morris; L Harrison; J Sosna; M Peterson; O Militano; S Foley; J Kurtzberg; M S Cairo Journal: Leukemia Date: 2014-06-18 Impact factor: 11.528
Authors: Evelyn Rustia; Leah Violago; Zhezhen Jin; Marc D Foca; Justine M Kahn; Staci Arnold; Jean Sosna; Monica Bhatia; Andrew L Kung; Diane George; James H Garvin; Prakash Satwani Journal: Biol Blood Marrow Transplant Date: 2016-05-29 Impact factor: 5.742
Authors: J M Talano; M A Pulsipher; H J Symons; O Militano; E B Shereck; R H Giller; L Hancock; E Morris; M S Cairo Journal: Bone Marrow Transplant Date: 2014-05-12 Impact factor: 5.483